NASDAQ · Biotechnology

Harmony Biosciences Holdings, Inc. (HRMY) Stock

$37.95 -0.84% NASDAQ: HRMY Healthcare

Valuation

MetricValue
Price$37.95
Market Cap$2.21B
P/E Ratio12.66
P/B Ratio2.30
P/S Ratio2.39
EPS (TTM)$2.71
52-Week High$43.49
52-Week Low$25.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE20.06%
ROA13.20%
ROCE20.25%
Gross Margin23.96%
Operating Margin23.96%
Net Margin18.88%
Debt/Equity0.15
Current Ratio3.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$305.0M$438.0M$582.0M$715.0M$868.0M
Operating Profit$88.0M$120.0M$192.0M$191.0M$208.0M
Net Profit$35.0M$181.0M$129.0M$145.0M$159.0M
EPS$0.58$2.97$2.13$2.51$2.71
Op Margin28.7%27.4%33.0%26.7%24.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$433.0M$674.0M$811.0M$999.0M$1.3B
Total Liabilities$247.0M$271.0M$344.0M$340.0M$401.0M
Cash$234.0M$244.0M$312.0M$453.0M$753.0M
Borrowings$196.0M$192.0M$194.0M$181.0M$240.0M

Latest News

Deutsche Bank Adjusts Price Target on Harmony Biosciences to $36 From $30, Maintains Hold Rating MT Newswires · Jun 30, 2026 Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? Zacks · Jun 29, 2026 HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase Zacks · Jun 29, 2026 Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline Zacks · Jun 29, 2026 Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance Simply Wall St. · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$99.0M$144.0M$219.0M$220.0M$348.0M
Investing Cash Flow$-101.0M$-142.0M$-47.0M$-69.0M$-40.0M
Financing Cash Flow$8.0M$9.0M$-104.0M$-2.0M$-3.0M
Net Cash Flow$6.0M$9.0M$67.0M$141.0M$300.0M
Free Cash Flow$98.0M$144.0M$219.0M$219.0M$348.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-10.04
EV / EBITDA6.87
FCF Yield15.46%
Quick Ratio3.45
Interest Coverage17.11
Return 1Y-4.99%
Return 3Y-2.11%
Return 5Y18.45%

Ownership

Insiders Held11.69%
Institutions Held103.37%
Institutions Float Held117.05%
Institutional HolderSharesReport Date
Blackrock Inc.7,070,0352026-03-31
FMR, LLC3,157,6392026-03-31
Vanguard Portfolio Management LLC2,714,3532026-03-31
American Century Companies Inc2,105,1792026-03-31
Vanguard Capital Management LLC2,102,3152026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APMDApnimed, Inc. $17.76 -2.66% 2.62 $739.36M 0.00%
CMPSCOMPASS Pathways plc $13.31 -0.60% -6.19 $1.28B 0.00%
LBRXLB Pharmaceuticals Inc $36.74 +0.14% -12.45 $1.19B 0.00%
NERVMinerva Neurosciences, Inc $2.35 -2.89% -0.08 $112.21M 0.00%

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (HRMY) stock trades at $37.95 with a market capitalization of $2.21B. The stock is valued at a price-to-earnings (P/E) ratio of 12.66, price-to-book of 2.30, price-to-sales of 2.39. Over the past 52 weeks the stock has ranged between $25.52 and $43.49, and currently trades 12.7% below its 52-week high.

On profitability, Harmony Biosciences Holdings, Inc. generates a return on equity (ROE) of 20.06%, above the typical market range of roughly 12-15%, return on capital employed of 20.25%, an operating margin of 23.96%, a net profit margin of 18.88%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.